- Trump threatens tariffs on imported generic drugs<figure><div><img src="https://imgproxy.divecdn.com/FZSdFBL2W8A453vDL0XpB2NIs52eHj5QA0Y0T_Dy_Bs/g:nowe:0:0/c:3200:1807/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0…BioPharma Dive · 2d ago↗ source
- Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drugWith Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…BioSpace · 2d ago↗ source
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.